$59B market cap (Merck, Rahway) advanced sac-TMT, an antibody-drug conjugate targeting HER2+ cancers, to Phase 3 efficacy win in 2026. ADC platform represents key growth vector amid competitive oncology landscape and portfolio diversification.
Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.
Notes, edits, or content requests — sent directly to James.